(RTTNews) - Shares of Atreca, Inc. (BCEL) are currently losing nearly 18% on Thursday morning despite no stock-specific news.
BCEL is currently trading at $15.11, down $3.31 or 17.96%, on the Nasdaq.
Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
The company on Wednesday announced the pricing of its previously announced underwritten public offering of 7 million Class A common stock and 781 thousand Class B common stock, each at a price to the public of $16.00 per share.
Gross proceeds to Atreca from the offering are expected to be $125.0 million.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
